Literature DB >> 2384137

Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents.

L F Sancilio1, L M Pinkus, C B Jackson, H R Munson.   

Abstract

Zacopride administered orally was more emetic in fed than in fasted ferrets. The emetic activity of zacopride (0.1 mg/kg p.o.) was inhibited (100%) by 0.1 mg/kg i.p. of zacopride and 1 mg/kg i.p. of ICS 205-930. Haloperidol (3.16 mg/kg i.p.) and prochlorperazine (3.16 mg/kg i.p.) were weakly effective. N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide, a 5-HT1P antagonist, was inactive. Thus, the emetic activity of zacopride, like that of cisplatin, is blocked by 5-HT3 receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384137     DOI: 10.1016/0014-2999(90)90094-m

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Characterization of the 5-hydroxytryptamine receptors mediating contraction in the intestine of Suncus murinus.

Authors:  F A Javid; R J Naylor
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  5-HT4 receptor mediated facilitation of the emptying phase of the peristaltic reflex in the guinea-pig isolated ileum.

Authors:  B Costall; R J Naylor; B R Tuladhar
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

Review 3.  5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.

Authors:  M S Aapro
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 4.  Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds.

Authors:  C Veyrat-Follet; R Farinotti; J L Palmer
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 5.  5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.

Authors:  R E Gregory; D S Ettinger
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.